← All indications
Neoplasm, Residual
Remnant of a tumor or cancer after primary, potentially curative therapy.
Drugs by status
Phase 4 trials (3)
Phase 3 trials (5)
Phase 2 trials (42)
- decitabine
- azacitidine
- anlotinib
- allogeneic natural killer cells
- atezolizumab
- avelumab
- venetoclax
- blinatumomab
- busulfan
- clofarabine
- fruquintinib
- tacrolimus
- naltrexone
- guadecitabine
- levetiracetam
- ipatasertib
- pembrolizumab
- dinutuximab
- pevonedistat
- carmustine
- carboplatin
- allogeneic hematopoietic stem cells
- ruxolitinib
- sirolimus
- cyclosporine
- mycophenolate
- cyclophosphamide
- allogeneic lymphocytes
- Anti-thymocyte Globulin (Rabbit)
- irradiated donor lymphocyte
- +12 more
Phase 1 trials (11)
- autologous natural killer cells
- cetuximab
- allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes
- anti-cd33 car-nk cells
- autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes
- t lymphocytes
- cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
- eli-002
- qn-030a
- cd33/cll1 dual car-nk cell
- trop2-car-nk
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (47)
- Incyte
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- Genentech
- MedImmune
- Genzyme
- Pfizer
- Fundació Sant Joan de Déu
- National Institutes of Health (NIH)
- Center for International Blood and Marrow Transplant Research
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Jena
- University of Pennsylvania
- Harvard University
- University of Washington
- Guangxi Medical University
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Ohio State University
- Rutgers University
- Stanford University
- University of Southern California
- Mayo Clinic
- University of British Columbia
- University of Chicago
- Vanderbilt University
- Shandong University
- University of Minnesota
- Astex Pharmaceuticals, Inc.
- +17 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (4)